15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering 4D Molecular Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $21.00 to $37.00, a moderate spread. The average target of $31.33 sits 114% above the current $14.64. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.03 next quarter toward $-4.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to 4D Molecular Therapeutics Inc.
As of Sep, 6 of 6 firms rate FDMT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
FDMT EPS & revenue forecast
EPS · NEXT QUARTER
$-1.03
Range $-1.11 – $-0.90 · 10 analysts · -339% YoY
Next period, 10 analysts expect 4D Molecular Therapeutics Inc to earn $-1.03 a share (range $-1.11 – $-0.90), versus $0.43 a year earlier. Full-year consensus is $-4.14, growing to $-4.09 the year after.
REVENUE · NEXT QUARTER
$3.7M
Range $0 – $10.0M · 10 analysts · -96% YoY
Revenue is expected to reach $3.7M (range $0 – $10.0M), -95.7% year-over-year. Full-year consensus is $12.8M, rising to $21.2M next year.
Top analysts covering 4D Molecular Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FDMT.
#1
Luca Issi
RBC Capital · Rank #1
Buy
$35.00+139.1% to target
Overall win rate
55%
+ Follow
#2
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$37.00+152.7% to target
Overall win rate
50%
+ Follow
#3
Geulah Livshits
Chardan Capital · Rank #85
Buy
$26.00+77.6% to target
Overall win rate
46%
+ Follow
#4
MC
Matthew Caufield
HC Wainwright & Co. · Rank #92
Buy
$36.00+145.9% to target
Overall win rate
54%
+ Follow
#5
TA
Tazeen Ahmad
B of A Securities · Rank #317
Buy
$40.00+173.2% to target
Overall win rate
47%
+ Follow
FDMT stock forecast FAQ
What is FDMT's average 12-month price target?+
The 6 analysts with a live target average $31.33 for 4D Molecular Therapeutics Inc over the next 12 months, ranging from a $37.00 high to a $21.00 low.
Is FDMT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for FDMT?+
The Street-high target is $37.00 (B. Riley Securities), and the Street-low is $21.00 (Jefferies). The average of all 6 active targets is $31.33.
How many Wall Street analysts cover FDMT?+
6 analysts have an active rating on 4D Molecular Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering FDMT?+
Among analysts who currently cover FDMT, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $35.00 target.
What is 4D Molecular Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.03 per share (range $-1.11 – $-0.90) across 10 analysts. Full-year EPS is projected at $-4.14, rising to $-4.09 the following year.
How much revenue is 4D Molecular Therapeutics Inc expected to report next quarter?+
Consensus revenue is $3.7M (range $0 – $10.0M). Full-year revenue is projected at $12.8M, growing to $21.2M next year.
Have analysts been upgrading or downgrading FDMT lately?+
As of Sep, 6 of 6 firms rate FDMT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FDMT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
